Loading
A phase 2 trial of Sonesitatug vedotin, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Capecitabine and Fluorouracil (5-FU) in oesophageal cancer, run by AstraZeneca, now recruiting.
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma is a phase 2 interventional study registered as NCT07069712 by AstraZeneca, with 100 participants planned, started 2025-07-17 and due to reach its primary completion in 2027-11-03. Interventions recorded: Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU) and FLOT Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sonesitatug vedotin, Rilvegostomig, Oesophageal and junctional adenocarcinoma, Capecitabine and the tag pipeline.
Shares Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Capecitabine and the tag pipeline.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, Fluorouracil (5-FU), Capecitabine and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Shares Parexel, AstraZeneca and the tag pipeline.
Shares Oesophageal and junctional adenocarcinoma, Fluorouracil (5-FU), Capecitabine, Oesophageal cancer and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/